Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + S-1 adjuvant therapy for resectable high-risk biliary tract cancer
ChiCTR2600135743Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tegafur in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 3 more, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 2-year recurrence-free survival rate. Started May 2024; status: completed.
02
Drugs
durvalumabtegafur
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancerhilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on ChiCTR2600135743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135743.